These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31002149)

  • 21. Evidence-based management of irritable bowel syndrome with diarrhea.
    Pimentel M
    Am J Manag Care; 2018 Jan; 24(3 Suppl):S35-S46. PubMed ID: 29372991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden.
    Fortea J; Prior M
    J Med Econ; 2013; 16(3):329-41. PubMed ID: 23216014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.
    Johansson PA; Farup PG; Bracco A; Vandvik PO
    BMC Gastroenterol; 2010 Mar; 10():31. PubMed ID: 20233451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
    Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis.
    Shah ED; Chang L; Salwen-Deremer JK; Gibson PR; Keefer L; Muir JG; Eswaran S; Chey WD
    Am J Gastroenterol; 2021 Apr; 116(4):748-757. PubMed ID: 33982945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review: the economic impact of irritable bowel syndrome.
    Inadomi JM; Fennerty MB; Bjorkman D
    Aliment Pharmacol Ther; 2003 Oct; 18(7):671-82. PubMed ID: 14510740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment.
    Canavan C; West J; Card T
    Pharmacoeconomics; 2016 Feb; 34(2):181-94. PubMed ID: 26497004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome.
    Häuser W; Marschall U; Layer P; Grobe T
    Dtsch Arztebl Int; 2019 Jul; 116(27-28):463-470. PubMed ID: 31431234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study].
    Marcellusi A; Viti R; Incorvaia C; Mennini FS
    Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
    Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
    PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The spectrum of irritable bowel syndrome: A clinical review.
    Gilkin RJ
    Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain.
    Nyrop KA; Palsson OS; Levy RL; Von Korff M; Feld AD; Turner MJ; Whitehead WE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):237-48. PubMed ID: 17593069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis.
    Schorling E; Lick S; Steinberg P; Brüggemann DA
    PLoS One; 2023; 18(4):e0283865. PubMed ID: 37018288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
    Didari T; Mozaffari S; Nikfar S; Abdollahi M
    World J Gastroenterol; 2015 Mar; 21(10):3072-84. PubMed ID: 25780308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010.
    Sethi S; Wadhwa V; LeClair J; Mikami S; Park R; Jones M; Sethi N; Brown A; Lembo A
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1338-46. PubMed ID: 24206371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homeopathy for treatment of irritable bowel syndrome.
    Peckham EJ; Nelson EA; Greenhalgh J; Cooper K; Roberts ER; Agrawal A
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009710. PubMed ID: 24222383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.